Your ovarian reserve doesn't have the last word
Ingenes' advanced technique that uses growth factors to improve the quality and quantity of your eggs. A real alternative to egg donation, backed by international science.
Ovagen™ is the ovarian regeneration technique developed at Ingenes that uses growth factors to improve the ovarian microenvironment and increase the quality and quantity of available eggs.
It's a real alternative for women with low ovarian reserve, advanced reproductive age, or poor response to hormonal stimulation who want to conceive with their own eggs. We are pioneers of the technique in Latin America.
- 0% of post-Ovagen™ cycles yield eggs for IVF
- 0% with embryos ready to transfer
- 0% pregnancy rate with transferable embryos
- +0 patients accompanied in the last year
Science that improves your ovarian microenvironment
The ovarian microenvironment is key to follicle development and egg maturation. Over time or due to medical conditions, this environment deteriorates. Ovagen™ revitalizes it.
-
Growth factors that regenerate
We apply nutrients, proteins, and growth factors that act directly on the ovary, promoting cellular regeneration and tissue rejuvenation.
-
Better stimulation response
A regenerated ovary responds better to hormonal stimulation, which translates into more eggs and higher quality per treatment cycle.
-
Healthier eggs, more viable embryos
By improving egg quality, we also reduce the risk of chromosomal anomalies. Result: healthier embryos, higher implantation rate, and a safer pregnancy.
A real alternative to egg donation
Ovagen™ is designed for women and couples who want to conceive with their own eggs and seek to optimize their chances before considering egg donation.
It is essential that the patient has sufficient ovarian mass and follicles that respond to stimulation. The initial diagnosis confirms this with hormonal studies, ultrasound, and ovarian reserve analysis.
- Women with low ovarian reserve
- Advanced reproductive age (35+)
- Poor response to hormonal stimulation in previous cycles
- Premature ovarian insufficiency
- Those who prefer to avoid egg donation
Ovagen™ figures at Ingenes
Over 200 patients accompanied in the last year alone. Cumulative results show why Ovagen™ has become a regional benchmark.
- Egg retrieval
86% of cycles with eggs for IVF
In 86% of post-Ovagen™ cycles we recover enough eggs to initiate In Vitro Fertilization, even in patients who previously didn't respond to stimulation.
- Transferable embryos
56% reach transfer
In 56% of cycles we achieve embryos ready for transfer. Combining Ovagen™ with PGT-A doubles the chances of having chromosomally healthy embryos.
- Pregnancy rate
42% with transferable embryos
With viable embryos after Ovagen™, pregnancy probability rises up to 42% (vs. 9% in low-reserve patients without the treatment).
Your path is unique. So is your plan.
We design a protocol tailored to you after understanding your story and your previous tests. No generic diagnoses or protocols.
Factors that can affect your eggs
Age is the most determining factor, but not the only one. Several conditions can reduce egg quality even in younger women.
-
Genetics and immunology
Hereditary alterations or an immune system that attacks the eggs can reduce egg quality regardless of age.
-
Oncological treatments
Chemotherapy and radiotherapy can damage the ovaries and reduce egg quality. Ovagen™ is an option to revitalize ovarian function after these treatments.
-
Hormonal and metabolic conditions
Polycystic Ovary Syndrome (PCOS, now PMOS), endometriosis, obesity, and smoking affect hormonal balance and egg quality.
-
Low reserve and low response
Some women have fewer eggs from birth or their ovaries don't respond well to stimulation. Ovagen™ improves both scenarios.
Pioneers in ovarian regeneration in Latin America
At Ingenes we have refined the Ovagen™ technique over years of clinical research. We collaborate with researchers from Cinvestav-IPN and publish studies in international scientific journals.
Our research team combines clinical practice with cutting-edge technology development, including Preimplantation Genetic Testing for Monogenic Diseases (PGT-M).
- Publications in Oxford Medical Case Reports and other indexed journals
- Collaboration with Cinvestav-IPN for advanced research
- Cutting-edge technology in internationally certified laboratories
- Personalized medical support in every cycle
Frequently asked questions
How does Ovarian Regeneration work?
Ovagen™ uses growth factors to improve the ovarian microenvironment and stimulate the production of better-quality eggs. It restores ovarian function, especially in women with low reserve or poor response to hormonal stimulation.
What is Ovarian Rejuvenation with A-PRP?
With A-PRP (Autologous Platelet-Rich Plasma) we draw a blood sample from the patient, process it to obtain platelet-rich plasma, and inject it into the ovaries. The procedure is outpatient, minimally invasive, and promotes cellular regeneration.
What are the main benefits?
It improves egg quality and ovarian function, especially in women with low reserve or advanced age. It increases pregnancy chances using one's own eggs, avoids egg donation, and offers an advanced solution for those who have had poor response in previous cycles.
Who is a candidate for Ovagen™?
Women with low ovarian reserve, poor stimulation response, advanced reproductive age, or premature ovarian insufficiency, as long as their ovaries maintain sufficient mass and responsive follicles. The initial diagnosis confirms this.
What scientific support does Ovagen™ have?
Ovagen™ is supported by multiple studies published in international scientific journals: Frontiers in Endocrinology, Journal of Clinical Medicine, Cureus, Cell Transplantation, Reproductive Sciences, Aging, and Molecular Biology Reports, among others. At Ingenes we have refined it over years and are a regional benchmark.
Do you identify with this journey?
Book your first consultation to evaluate whether Ovagen™ is the best option for your story. We walk with you with science and experience from day one.
Contact us